McDermott Advises DiogenX in Series A financing Round

McDermott Will & Emery advised DiogenX, a biotechnology company focused on regenerating insulin-producing beta cells for the treatment of diabetes, in a Series A financing round.

DiogenX is raising EUR27.5 million to advance its lead program into Phase I in Type 1 diabetes patients.

New investors Roche Venture Fund, Eli Lilly and Company and Omnes joined the round alongside existing investors Boehringer Ingelheim Venture Fund (BIVF), JDRF T1D Fund and AdBio partners.

The McDermott team that advised DiogenX comprised:

• Anthony Paronneau, partner, Fanny Rech, counsel and Ludivine Rabreau, associate.

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.